Skip to main content
Top
Published in: Clinical Rheumatology 5/2024

15-03-2024 | Correction

Correction to: Effectiveness and safety of sarilumab in patients with rheumatoid arthritis: A multicenter, retrospective, inverse probability of treatment-weighted analysis based on the FRAB-registry

Authors: Hiroshi Harada, Masakazu Kondo, Akira Maeyama, Takaaki Fukuda, Satoshi Ikemura, Eisuke Shono, Tomomi Tsuru, Yasushi Inoue, Seiji Yoshizawa, Hiroaki Niiro, Yasuharu Nakashima

Published in: Clinical Rheumatology | Issue 5/2024

Login to get access

Excerpt

Correction to: Clinical Rheumatology
Metadata
Title
Correction to: Effectiveness and safety of sarilumab in patients with rheumatoid arthritis: A multicenter, retrospective, inverse probability of treatment-weighted analysis based on the FRAB-registry
Authors
Hiroshi Harada
Masakazu Kondo
Akira Maeyama
Takaaki Fukuda
Satoshi Ikemura
Eisuke Shono
Tomomi Tsuru
Yasushi Inoue
Seiji Yoshizawa
Hiroaki Niiro
Yasuharu Nakashima
Publication date
15-03-2024
Publisher
Springer International Publishing
Published in
Clinical Rheumatology / Issue 5/2024
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-024-06907-6

Other articles of this Issue 5/2024

Clinical Rheumatology 5/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine